Skip to main content

Advertisement

Table 3 Outcomes and costs of base-case analysis

From: Using a dynamic adherence Markov model to assess the efficiency of Respiratory Medication Therapy Adherence Clinic (RMTAC) on asthma patients in Malaysia

Outcome RMTAC + UC UC
Life years 27.88 (27.73–28.00) 27.76 (27.58–27.93)
QALYs 9.61 (7.97–11.29) 9.43 (7.85–11.00)
Number of hospitalization 16.60 (10.73–23.99) 22.22 (14.20–31.40)
Costs ($)* 16,370.35 (13,410.62–20,220.91) 18,780.21 (14,822.97–23,577.53)
ICER (vs. UC)
$ per QALY gained − 13,639.40 (− 109,556.90 to 104,445.54)
$ per hospitalization averted − 428.93 (− 521.27 to (− 328.69))
  1. All values are expressed in mean (95% credible intervals)
  2. ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; RMTAC, Respiratory Medication Therapy Adherence Clinic; UC, usual care
  3. * Cost is expressed in 2014 US dollars ($)